2,771 results on '"Munshi, Nikhil C"'
Search Results
2. Author Correction: The Cyclophilin A–CD147 complex promotes the proliferation and homing of multiple myeloma cells
3. Venetoclax resistance leads to broad resistance to standard-of-care anti-MM agents, but not to immunotherapies
4. Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial
5. Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma
6. Author Correction: Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity
7. Lymphopenia predicts poor outcomes in newly diagnosed multiple myeloma
8. More intensive therapy has a better effect for frail parents with multiple myeloma
9. Elevated APE1 Dysregulates Homologous Recombination and Cell Cycle Driving Genomic Evolution, Tumorigenesis, and Chemoresistance in Esophageal Adenocarcinoma
10. Single-cell profiling in multiple myeloma: insights, problems, and promises
11. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
12. CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma
13. High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma
14. Peripheral blood monocyte count is a dynamic prognostic biomarker in multiple myeloma
15. A MIR17HG-derived long noncoding RNA provides an essential chromatin scaffold for protein interaction and myeloma growth
16. Improving NK cell function in multiple myeloma with NKTR-255, a novel polymer-conjugated human IL-15
17. Ubiquitin receptor PSMD4/Rpn10 is a novel therapeutic target in multiple myeloma
18. Quality of life, psychological distress, and prognostic perceptions in caregivers of patients with multiple myeloma
19. Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single-cell level by QM-FISH
20. Therapeutic activation of G protein-coupled estrogen receptor 1 in Waldenström Macroglobulinemia
21. In-depth analysis of alternative splicing landscape in multiple myeloma and potential role of dysregulated splicing factors
22. Proposal for harmonizing the reporting of infections during treatment with bispecific antibodies in multiple myeloma
23. Lack of differential impact of del17p on survival in African Americans compared with White patients with multiple myeloma: a VA study
24. Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy
25. Risk factors in multiple myeloma: is it time for a revision?
26. Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström Macroglobulinemia
27. Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set
28. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma
29. Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling
30. Retraction: Insulin-like Growth Factor-1 Induces Adhesion and Migration in Human Multiple Myeloma Cells via Activation of β1-Integrin and Phosphatidylinositol 3′-Kinase/AKT Signaling
31. Retraction: Mechanisms by which SGN-40, a Humanized Anti-CD40 Antibody, Induces Cytotoxicity in Human Multiple Myeloma Cells: Clinical Implications
32. Retraction: Nuclear Factor-κB p65 Mediates Tumor Necrosis Factor α-induced Nuclear Translocation of Telomerase Reverse Transcriptase Protein
33. Retraction: Effects of Oligonucleotide N3′→P5′ Thio-phosphoramidate (GRN163) Targeting Telomerase RNA in Human Multiple Myeloma Cells
34. Retraction: Cytokines Modulate Telomerase Activity in a Human Multiple Myeloma Cell Line
35. Abstract P24: GABARAP deficiency drives resistance to immunogenic chemotherapy in multiple myeloma
36. Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma
37. Idecabtagene Vicleucel (ide-cel) Versus Standard Regimens (SRs) in Triple-Class–Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa-3 Subanalysis of Black Patients (pts)
38. Biomarker Correlates of 3 Year Response in Cartitude-1: A Phase 1b/2 Open-Label Study of Ciltacabtagene Autoleucel in Patients with Relapsed or Refractory Multiple Myeloma
39. Impact of treatment effect on MRD and PFS: an aggregate data analysis from randomized clinical trials in multiple myeloma
40. A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci
41. Integrated genomics and comprehensive validation reveal drivers of genomic evolution in esophageal adenocarcinoma
42. The DNA methylation landscape of multiple myeloma shows extensive inter- and intrapatient heterogeneity that fuels transcriptomic variability
43. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma
44. Dysregulated APOBEC3G causes DNA damage and promotes genomic instability in multiple myeloma
45. Amplification and overexpression of E2 ubiquitin conjugase UBE2T promotes homologous recombination in multiple myeloma
46. Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells
47. Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs
48. Acute lymphoblastic leukemia with myeloid mutations is a high-risk disease associated with clonal hematopoiesis
49. ABL1 kinase plays an important role in spontaneous and chemotherapy-induced genomic instability in multiple myeloma
50. Differentiation of BCMA-specific induced pluripotent stem cells into CD8ab+ T cells targeting myeloma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.